MRP14 (S100A9) Protein Interacts with Alzheimer Beta-Amyloid Peptide and Induces Its Fibrillization by Zhang, Ce et al.
MRP14 (S100A9) Protein Interacts with Alzheimer Beta-






4, Johan R. C. van der Maarel
2
1Department of Medical Biochemistry and Biophysics, Umea ˚ University, Umea ˚, Sweden, 2Department of Physics, National University of Singapore, Singapore, Singapore,
3Laboratory of Stem Cell and Tissue Engineering, Chongqing Medical University, Chongqing, China, 4Umea ˚ Centre for Molecular Medicine (UCMM), Umea ˚ University,
Umea ˚, Sweden
Abstract
Increasing evidence supports the contribution of local inflammation to the development of Alzheimer’s disease (AD)
pathology, although the precise mechanisms are not clear. In this study, we demonstrate that the pro-inflammatory protein
S100A9 interacts with the Ab1–40 peptide and promotes the formation of fibrillar b-amyloid structures. This interaction also
results in reduced S100A9 cytotoxicity by the binding of S100A9 toxic species to Ab1–40 amyloid structures. These results
suggest that secretion of S100A9 during inflammation promotes the formation of amyloid plaques. By acting as a sink for
toxic species, plaque formation may be the result of a protective response within the brain of AD patients, in part mediated
by S100A9.
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Introduction
Knockdown of S100A9 expression improves cognition function
in Alzheimer’s disease model mice (Tg2576) and these animals also
exhibit reduced amyloid plaque burden [1]. However, a
mechanistic link between S100A9 and Alzheimers disease
pathology has not been shown. S100A9 protein is a reliable
marker of inflammation [2]. Infiltrating macrophages express
S100A9 in the event of acute or chronic inflammation [3,4].
S100A9 and A8 are co-expressed mainly by phagocytes in a
variety of inflammatory conditions, including rheumatoid arthritis,
allograft rejection, inflammatory bowel, and lung diseases [5,6].
Inflammatory disorders such as chronic bronchitis, cystic fibrosis,
and rheumatoid arthritis are also associated with elevated plasma
levels of S100A9 [7,8].
It has been speculated that inflammation is directly related to
Alzheimer’s disease. Studies performed in transgenic animals
suggest that cerebral amyloid deposition is increased in inflam-
matory conditions [9]. In these transgenic animals, amyloid
plaques do not develop unless inflammation is induced. Heneka et
al. reported that in certain conditions related to chronic stress,
astrocytes secreting S100 proteins assemble at the site of amyloid
plaques, which may serve to prolong neuroinflammation [10]. An
additional report shows microglial activation in early stages of AD
[11]. These results indicate that early and local inflammatory
events contribute to neuronal dysfunction and the formation of
amyloid plaques at this and later stages of AD, respectively.
To investigate the relationship between S100A9 and amyloid
plaques, we have studied the interaction between the main
component of the amyloid plaque (Ab1–40) and S100A9 by
exploring the conformational and structural transition of species
generated between them by atomic force microscopy (AFM),
circular dichorism (CD), polyacrylamide gel electrophoresis
(PAGE) and the Thioflovin-T assay (ThT). We observed that,
whilst retaining its native structure, S100A9 triggers and promotes
the formation of b-amyloid aggregates. To investigate the effect of
S100A9/Ab mixtures on cells of neural origin, we employed the
WST-1 assay on the neuroblastoma SH-SY5Y cell line. Our
results show that freshly dissolved Ab1–40 is not toxic to neural
cells, whereas S100A9 shows strong cytotoxicity. The addition of
Ab1–40 significantly reduces S100A9 cytotoxicity. Our study
provides direct physical evidence that S100A9 triggers and
accelerates Ab1–40 amyloid formation, which indicates that
amyloid plaque formation is related to inflammation and may
be the result of a protective response.
Results
Ab1–40 fibrillization induced by S100A9
Ab1–40/S100A9 mixtures containing various additions of Ab1–
40 were examined using atomic force microscopy (AFM). After
1 day (d) of incubation at 370C, massive aggregates were produced
in the form of round-shaped oligomers, proto-filaments and
elongated thick fibrils (Fig. 1). Randomly distributed on mica
surface, the round-shaped oligomers had a diameter of 80 nm and
a height of 10 nm. The proto-filaments carried a height of 2.7 nm,
a width of 50 nm and an average length of 300 nm. They were
dimensionally similar to those observed in the Ab control samples
after 3 d of incubation under the same condition (Fig. S1). The
thick fibrils were less abundant and had a height of 8 nm, a width
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these thick fibrils are formed by the inter-twisting of protofilaments
[12]. After incubation for 3 d, there were no obvious transitions in
the cross-sectional dimensions of these structures (Fig. 1). The
proto-filaments developed into a more extended form with a width
of 50 nm and a height of 2 nm. The filaments inter-connected
with each other into network-like structures. The co-localization of
protofilaments (2 nm in height) and mature fibrils (5 nm in height)
supports our supposition that the fibrillar species are initiated from
protofilaments.
To identify the origin of massive aggregates, S100A9 was
titrated with various concentrations of Ab1–40 and incubated at
370C for 3 d (Fig. 1). As the Ab1–40 concentration was reduced,
the quantity of aggregates (fibrils and oligomers) decreased
dramatically. Using AFM cross-section measurements, we found
that these fibrillar structures shared comparable dimensions (2 nm
in height and 30 nm in width). Short proto-filaments carrying a
similar cross-sectional dimension were observed for concentrations
of Ab1–40 as low as 0.02 mM. This similarity suggests that these
fibrillar aggregates originated from Ab1–40. In conclusion,
compared with the amyloid development in Ab1–40 control
samples (Fig. S1: It took 3 d for Ab1–40 to develop small quantities
of amyloid fibrils with a height of 2 nm), the presence of S100A9
promotes the rate of formation and the quantity of Ab1–40
amyloid species produced.
Kinetics of amyloid formation
The kinetics of S100A9/Ab1–40 amyloid formation was
monitored using the ThT-binding assay (Fig. 2). The specific
interaction of ThT with cross-b-sheet-containing amyloids, leads
to an increase in fluorescence emission. The time dependence of
amyloid formation depended primarily on the concentrations of
Ab1–40. In contrast to the Ab1–40 (0.2 mM) control samples, a
sharp increase in ThT intensity was observed with the addition of
S100A9 (0.02 mM). After 2 d to 3 d of incubation, the ThT
intensity reached its maximum value. A plateau was attained
following a decline in the ThT intensity after 7 d to 8 d of
incubation. It is possible that the decline in the relative ThT value
was induced by the formation of massive aggregates, which is
consistent with our AFM observations (Fig. 1). When the
concentration of Ab was decreased to 0.1 mM, the relative ThT
intensity dropped from 2.0 to 1.6 in spite of the increasing S100A9
concentration (from 0.02 mM to 0.2 mM). The variation in
amyloid formation kinetics is consistent with the hypothesis that
amyloid formation is largely induced by Ab1–40 rather than by
S100A9.
Transitions in S100A9/Ab1–40 secondary structures
The transition in secondary structures during the development
of S100A9/Ab1–40 aggregates was monitored using far UV
circular dichorism (CD). The CD spectrum of the control sample
containing only Ab1–40 (0.2 mM) was dominated by random coil
structure and characterized by a pronounced negative peak
centered at the wavelength below 200 nm after 1 d of incubation
at 370C (Fig. 2) [13]. With the addition of trace amount of S100A9
(0.02 mM) under the same conditions, spectra typical of b-sheet
structures (centered at 217 nm) were observed. As there was no
obvious secondary-structure transition for the samples containing
only S100A9 or Ab1–40, we conclude that this evolution is caused
by the interaction between these two proteins.
To explore the effect of Ab peptide on the secondary structure
of S100A9, S100A9 protein was incubated with various concen-
trations of Ab1–40 for 3 d and 7 d. The CD spectra were
characterized by two negative peaks centered at 208 nm and
222 nm (Fig. S2). There was little change in the spectra following
the addition of Ab1–40 and incubation at 370C for 3 d and 7 d.
The occurrence of S100A9 amyloid formation was excluded by a
comparison with S100A9 samples exposed to extreme conditions
(pH 3.0 and continuous shaking at 800 rpm). Under these
conditions, S100A9 lost its native structure (a -helix) and took
the form of b-sheet after 3d of incubation (Fig. S4). This transition
in the secondary structures of S100A9 is consistent with the
downward shift of monomer and dimer band positions in SDS
PAGE.
The transition in the secondary structures was exaggerated,
when the spectra of S100A9 alone were subtracted from the
spectra of the mixtures (Fig. 3). Following incubation for 3 d, the
difference spectra of the mixtures showed a negative peak with a
minimum below 200nm, which is thought to represent random-
coil structure. It is worth noting that the absolute values of the
Figure 1. AFM images of freshly dissolved Ab1–40 peptide
(0.2 mM) and S100A9 protein (0.02 mM) mixture, incubated at
pH 7.4 and 370C for (a) 1 d; and (b) 3 d. S100A9 (0.2 mM) with (c) Ab1–
40 (0.1 mM) ; (d) Ab1–40 (0.02 mM) incubated at pH 7.4 and 370C for 3
d. The scale bars denote 1000 nm for Fig. (a), 1200 nm for (b), 600 nm
for (c) and 600 nm for (d).
doi:10.1371/journal.pone.0032953.g001
Figure 2. ThT and CD spectra of S100A9/Ab1–40 (0.2 mM)
complex. (a) Kinetics of S100A9/Ab1–40 mixture amyloid formation at
pH 7.4 and 370C monitored by the thioflavin-T assay. Rhombuses
correspond to 0.2 mM Ab1–40. Squares correspond to 0.2 mM S100A9
and 0.1 mM Ab1–40. Circles correspond to 0.02 mM S100A9 and
0.2 mM Ab1–40 (b) CD spectra of Ab1–40 peptide (0.2 mM), S100A9
(0.02 mM) and their mixture, incubated at pH 7.4 and 370C for 1 d.
doi:10.1371/journal.pone.0032953.g002
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40. Prolonged incubation of the mixture with lower concentrations
of Ab1–40 (0.002 mM and 0.01 mM) for 7 d resulted in a decrease
in the absolute value of the ellipticity from 2 to 1. Such transition
could represent a shift from random-coil to orderly structures [14].
Unlike other samples, when the Ab1–40 concentration reached
0.02 mM, the spectra exhibited a shape that is typical for b-sheet
structures. After 7 d of incubation, the negative peak shifted from
206 nm (3 d) to 217 nm. This change denotes the formation of a
large quantity of b-sheet structures [13,14]. Given that the
difference CD spectra were obtained by subtracting the S100A9
signal, we believe the transition to b-sheet structure is induced by
Ab1–40. Considering the lack of transition in the SDS PAGE
measurements following the addition of Ab1–40, we believe that
the S100A9/Ab1–40 interaction does not result in any change in
S100A9 secondary structures.
With prolonged incubation (9 d), minor distinctions were
observed in the 200 to 230 nm wavelength range (Fig. 3). The two
negative peaks that originate from a -helix structures showed a
tendency to fuse. After incubation for 1 d, the negative peak that
centered at 222 nm nearly disappeared and an enhancement in
the amplitude of the peak at 208 nm was observed. After 3 d of
incubation, there was a decline in the amplitude of the negative
peak and a shift in the peak position to 209 nm. The two negative
peaks became even less evident when the samples were maintained
at 370C for 9 d. The distance between peaks decreased from
14 nm (208 nm to 222 nm) to 9 nm (210 nm to 219 nm). Taken
together, the results from AFM, ThT and CD analyses suggest that
S100A9 retains its secondary structures throughout development,
and the conformational and structural changes were caused by
amyloid formation from the Ab peptide.
Effect of Ab1–40 on S100A9 cytotoxicity
The effect of S100A9, Ab1–40 and their aggregates on the
viability of SH-SY5Y neuroblastoma cells was assessed using the
WST-1 assay. In viable cells, WST-1 undergoes reduction by
mitochondrial dehydrogenases (succinate-tetrazolium reductase
system) to soluble formazan, which serves as an indicator of the
number of metabolically active cells. The effect of Ab1–40 on
S100A9-induced cytotoxicity was investigated by pre-mixing
S100A9 with various concentrations of Ab1–40 and incubating
the samples with SH-SY5Y neuroblastoma cells for 1 d to 3 d
(Fig. 4). During the first day of incubation, at least 0.04 mM Ab1–
40 was required to inhibit the cell cytotoxicity of S100A9
(increasing cell survival to 90% from 70%). After 2 d of incubation,
a 50% increase in cell viability (from 30% to 80%) was observed
for Ab1–40 concentrations exceeding 0.2 mM (0.4 mM and
0.2 mM). Although the cell survival rate for all samples dropped
greatly on the third day of incubation, the addition of excessive
amounts of Ab1–40 (0.2 mM and 0.4 mM) increased the cell
viability from 10% to 30%. We concluded that the cytotoxicity of
S100A9 in SH-SY5Y cells is greatly suppressed by the presence of
sufficient amounts of Ab1–40 peptide (more than 0.2 mM Ab1–40
for 0.02 mM S100A9).
Characterization of the interaction between Ab1–40 and
S100A9
To explore the interaction between S100A9 and Ab1–40 during
incubation with cells, the mixtures and their corresponding
controls (S100A9 and Ab1–40 only) were analyzed using sodium
dodecyl sulfate (SDS) and native polyacrylamide gel electropho-
resis (PAGE). No significant shifts in protein band positions were
observed (Fig. 5). According to the bands generated by the control
samples (containing only S100A8, A9, or culture media alone), the
uppermost band corresponds to components of the media and the
lower two bands represent the S100A9 monomer and homodimer,
respectively. Because there was no change in the position of the
S100A9 bands, it appears that S100A9 maintained its native
structure during incubation with the cells. The structural stability
of S100A9 was further verified by comparison with the samples
exposed to harsh conditions (pH 3.0 and continuous shaking at
800 rpm). After 1 day of shaking at acidic pH, the band position of
S100A9 shifted significantly, indicating the formation of more
compact, faster migrating structures. A downward shift in band
position corresponds to S100A9 amyloid formation, thereforem
the absence of changes could indicate an absence of S100A9
amyloid formation during incubation with the cells.
Figure 3. Difference CD spectra of S100A9 (0.2 mM) with the
addition of various concentrations Ab1–40 peptide (0.002 mM
to 0.1 mM) i n c u b a t e da tp H7 . 4a n d3 7 0C for (a) 3 d; (b) 7 d. The difference
CD spectra are obtained by subtracting the ellipticity of the mixture with
the ones containing only S100A9 (0.2 mM). (c) Ellipticity of S100A9
(0.2 mM) and Ab1–40 (0.2 mM) mixture during 9 d of incubation at pH 7.4
and 370C. (d) Detailed features of panel c.
doi:10.1371/journal.pone.0032953.g003
Figure 4. Measurements of NHSY5Y cell line viability by WST1
assay in the presence of 0.02 mM S100A9 and various S100A9/
Ab1–40 mixtures. The S100A9 concentration remained 0.02 mM. The
concentration of Ab1–40 addition varied from 0.02 mM to 0.4 mM. In
control experiments, the cells were incubated in DMEM cell culture
buffer alone and the cell viability was equal to 100%.
doi:10.1371/journal.pone.0032953.g004
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estimated by integrating the intensities of all bands using Image J
software. Based on the SDS PAGE data, the freshly dissolved
S100A9 contained 74% monomers and 26% homodimers. After
incubation with cells for 3 d, the fraction of homodimer dropped
to 8.4%, which suggests that the reduction in the quantity of
S100A9 dimers is caused by its interaction with cells. A similar
decrease in the S100A9 dimer content was observed when S100A9
was mixed with various concentrations of Ab1–40 (Fig. 6).
Accompanied by a dramatic increase in the quantity of large
aggregates at the top of the gel, a declining intensity in the dimer
bands was observed for increasing Ab1–40 doses, which indicates
the consumption of S100A9 dimers by Ab1–40. The fraction of
S100A9 dimers was 30% at 0.002 mM Ab1–40, 18% at 0.01 mM
Ab1–40, 14% at 0.02 mM Ab1–40 and 10% with 0.1 mM Ab1–
40. Native PAGE revealed a band for Ab1–40 monomers when
the concentration of Ab1–40 exceeded 0.1 mM. Given that
S100A9 alone contained 74% monomers and 26% homodimers,
0.2 mM S100A9 solution contains 0.15 mM monomers and
0.025 mM dimers. If Ab1–40 interacts with the S100A9
monomer, the reaction could consume at least 0.15 mM of
Ab1–40, which is inconsistent with the existence of an Ab1–40
band in the presence of 0.1 mM Ab1–40. Conversely, 0.025 mM
S100A9 dimers could consume 0.02 mM Ab1–40. Considering
the decrease in the amount of S100A9 dimers and the absence of
an Ab1–40 band for Ab1–40 concentrations below 0.02 mM, we
believe that there is a specific interaction between the S100A9
dimer and Ab1–40 that does not involve S100A9 monomer.
Moreover, there was no additional band for S100A9/Ab1–40
hetero-dimer or any other visible complexes. Thus, it can be
assumed that these proteins are not stabilized in low-molecular-
weight structures. It is possible that S100A9 can serve at the Ab
nucleation or fibrillation stages. The rapid formation of Ab1–40
amyloid structures contributes to the absence of specific stable
complexes between S100A9 and Ab1–40 in low-molecular-weight
forms.
Discussion
The induction of the S100A9 gene was found in the brains of
AD patients and AD animal models, Tg2576 and CT-Tg mice [1].
This observation, together with our results, suggests that S100A9 is
responsible for the formation of AD amyloid plaques. The detailed
molecular mechanism remains however, unknown. Therefore, we
focused our research on the role of S100A9 in Ab amyloid
formation and interaction with neuron origin cells.
The consequences of S100A9/Ab1–40 interaction were inves-
tigated using AFM and CD. When S100A9 was mixed with Ab1–
40, large quantities of amyloid aggregates (fibrils and oligomers)
were formed (Fig. 1). The height of the fibrils was 2 nm, which is
similar to the values pertaining to mature Ab1–40 amyloid fibrils
(Fig. S1). Conformational variations with different Ab concentra-
tions identified Ab1–40 as the origin of amyloid formation (Fig. 1).
In contrast to the lack of transition in the S100A9 secondary
structure, Ab1–40 is responsible for the small changes seen in CD
spectra (Fig. 3). The possibility of S100A9 amyloid formation was
excluded by comparing S100A9 CD spectra in Fig. 3 with those of
S100A9 exposed to harsh conditions (pH 3.0, shaking) (Fig. S3).
The formation of S100A9 amyloid structure not only induced the
transition to b-sheet structure accompanied by the formation of
small filaments (1 nm in height), but also increased cell viability
(Fig. S4). The reduction in S100A9 cytotoxicity induced by the
addition of Ab1–40 was further verified by a luminescent
cytotoxicity assay of neuron cells (Fig. S5). Sharing the same
protective effect against S100A9 cytotoxicity, Ab1–40 monomer
was more efficient than Ab1–40 plaques. The higher cell survival
rate with Ab1–40 monomers compared to the ones of the plaques
is consistent with our AFM observation that S100A9 interacted
with freshly dissolved Ab peptides. Possibly, at the same peptide
concentration, the pre-formed amyloid plaques decrease Ab1–40
monomer quantity and S100A9 consumption, which was observed
as an increased cytotoxicity in the luminescent cytotoxicity assay.
The Ab/S100A9 interaction was further studied using the peptides
Ab1–16, Ab12–14 and Ab1–42 (Fig. S5). Similar to the case with
Ab1–40, S100A9 cytotoxicity was greatly reduced upon addition
of Ab12–14 and Ab1–42. This was accompanied by the formation
of large quantities of amyloid aggregates (Fig. S6). It is worth
noting that the Ab/S100A9 interaction did not only inhibit
S100A9 cytotoxicity, but also suppressed the toxicity of Ab1–42.
In contrast, the addition of Ab1–16 brought no effect on S100A9
cytotoxicity and no emergence of amyloid fibrillar structures. As
the major difference between Ab1–16 and other Ab peptides is the
absence of a hydrophobic core, we conclude that the hydrophobic
core (L17V18F19F20A21) is essential for the S100A9 and Ab
peptide interaction. In summary, S100A9 interacts with Ab1–40
and induces Ab amyloid formation whilst retaining its native
structures. This specific interaction reduces the quantity of toxic
S100A9 species and thus decreases S100A9-mediated cytotoxicity.
With a constant amount of S100A9 monomers, we observed a
great decrease in S100A9 dimer content from 26% to 8% (Fig. 5).
Such variation reflects the consumption of S100A9 dimers via
interaction with cells, which does not involve S100A9 monomers.
Since S100A9, apparently via the activity of the dimmer, induces
cell death, the reduction in cytotoxicity induced by the addition of
Ab1–40 could be related to its specific interaction with S100A9
dimers. The hypothesis is supported by titrating S100A9 with
different dose of Ab1–40. With increasing concentrations of Ab1–
40, amount of S100A9 dimer deceased dramatically (Fig. 6).
Additionally, more aggregates are formed as indicated by the
increasing band intensity corresponding to the wells. Therefore, it
is possible that the interaction between S100A9 dimers and Ab1–
40 reduces the number of toxic S100A9 dimers, leading to an
increase in cell viability.
S100A9 homodimer is shown to be expressed independently
during inflammation [15,16]. It has the ability to induce
neutrophil immobilization and bind both Ca and Zn ions
[17,18]. Structurally, the S100A9 monomer consists of 4 a-helices
(H1,H2,H3 and H4), a long carboxy-terminal tail and a hinge
region between H2 and H3. Through hydrophobic interactions,
the C- and N-teminus of helices (H1 and H1’;H4 and H4’) from
Figure 5. Electrophoresis of S100A9 incubated with NHSY5Y
cells. (a) and (c) SDS PAGE; (b) Native PAGE. Panel (a) has the following
designations: column 1 corresponds to the ladder; 2 to S100A9
(0.2 mM); 3 to cell culture buffer DMEM; 4 to S100A9 (0.04 mM) with
cells in DMEM for 3 d; 5 to S100A9 (0.01 mM) with cells in DMEM. In
panel (b), 1 to S100A9 (0.2 mM); 2 to DMEM; 3 to S100A9 (0.04 mM)
with cells in DMEM for 3 d. (c) 0.2 mM S100A9 at pH 3.0 and 7.4. The
data was obtained by several experiments, and integrated together
according to the ladders.
Inflammation and Alzheimer’s Disease (AD)
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antiparallel-packed hydrophobic core [19]. Because the electron
density of 28 residues in C-terminal tail is low and the residues are
mostly hydrophilic, it is believed that the residues do not
participate in electrostatic and hydrophobic protein-protein
interactions [19]. As an exposed part of the intra-molecule
hydrophobic cluster, the hinge region is identified as a target-
binding site for proteins [20]. The interaction between Ab1-40
and S100A9 is possibly initiated by binding to S100A9 hinge
region. According to our previous simulation results, the contact of
the Ab12-24 hydrophobic core (L17V18F19F20A21) leads to the
formation of b-sheet structures, which then act as a seed for further
amyloid formation [21]. Besides aggregation, proper stacking
(parallel or anti-parallel) is required, which demands a specific
residue sequence. The hinge region of S100A9 consists of 11
residues (Leu45-Asn55) (Fig. 7). Similarly to Ab peptides, the hinge
region has a hydrophobic core (L44Q45N46F47L48), following
which K (50, 51, 54) residues are positively charged and E52 is
negatively charged. By electrostatic interaction, E22D23 residues
pair with K50K51 residues. Such stacking allows Ab peptide
molecules to be aligned in a certain direction. As the anti-parallel
stacking is energetically preferred for Ab amyloid formation at
physiological pH, it is plausible that Ab amyloid formation is
initiated by binding of Ab peptide molecules to different sites of
S100A9 [20]. The S100A9 homodimer is formed by anti-parallel
stacking of two monomers. Accordingly, the binding of Ab
peptides to the hinge regions of two monomers provides the
possibility of anti-parallel stacking. This is consistent with our
assumption that the S100A9 homodimer interacts with Ab1–40
and our observation of the interactions between S100A9, Ab12–
24, and Ab1–42 peptide. Similar to Ab1–40, Ab12–24, and Ab1–
42 amyloid formation was greatly promoted by S100A9, which
emphasizes the importance of the Ab hydrophobic core (Fig. S6).
With no hydrophobic core (L17V18F19F20A21), Ab1-16 showed
no obvious change upon addition of S100A9 in both AFM and
Cytotoxicity experiments.
Overall, the results of this study, combined with those in
previous reports, suggest that Ab amyloid production is induced by
the pro-inflammatory protein S100A9. The Ab-induced reduction
of cytotoxicity indicates that the formation of AD amyloid plaques
could be a beneficial response to inflammation. It ameliorates the
potentially destructive effects of inflammatory molecules such as
S100A9. S100A9-induced Ab amyloid formation also explains the
presence of amyloid plaques in normal aged brain [22,23]. Further
computer simulations will be conducted to elucidate the
interaction between S100A9 and Ab peptides.
Figure 6. Electrophoresis and gas-phase electrophoretic mobility molecular analysis (GEMMA) of S100A9 and S100A9/Ab1–40
mixture. (a) SDS PAGE of S100A9 with (1) 0.002 mM; (2) 0.01 mM; (3) 0.02 mM; (4) 0.1 mM Ab1–40 and native PAGE of (5) 0.2 mM S100A9 with
0.01 mM Ab1–40; (6) 0.2 mM S100A9 with 0.1 mM Ab1–40; (7) 0.1 mM Ab1–40; (8) 0.01 mM Ab1–40. The final concentration of S100A9 is 0.2 mM.
The data was obtained by several experiments, and integrated together according to the ladders. (b) Size distribution of S100A9 monomer and dimer
at pH 7.4 and 3.0 examined by gas-phase electrophoretic mobility molecular analysis (GEMMA). The red columns represent S100A9 at pH 7.4. The
blue ones represent S100A9 at pH3.0.
doi:10.1371/journal.pone.0032953.g006
Figure 7. Amino acid sequence alignment of S100A9 in the
hinge region and Ab12–24 peptide. The hydrophobic cores of both
proteins are marked in red. The charged residues are indicated with
their approximate charges. All sequences were obtained from the
SWISS-PORT protein database [26].
doi:10.1371/journal.pone.0032953.g007
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Sample preparation
The proteins used in these experiments were recombinant
S100A9 (MRP14) and Ab1-40 obtained from Alexo Tech
AB(Umea, Sweden); Ab1-42 and Ab1-16 (Innovagen, Sweden).
All experiments were performed with Ab peptide concentrations of
0.02 to 0.2 mM and S100A9 concentrations of 0.02 to 0.2 mM.
S100A9 protein solutions were prepared in 10 mM Tris-HCl
buffer at pH 7.4, and dialyzed to pH 3.0 in 20 mM Glycine buffer
using Slide-A-Lyzer Dialysis Cassettes (Thermo Scientific, USA) at
40C. We dissolved Ab peptide at low temperatures (ice water)
following a protocol released previously [24]. The chilled Ab
peptide powder was initially dissolved in 10 mM NaOH at a
concentration above 1 mg/ml and sonicated in an ice water bath
for 1 min. Finally, a trace amount of 1 M NaH2PO4 buffer was
added to adjust the sample to pH7.4 and 3.0. All other chemicals
were purchased from Sigma unless mentioned differently.
Amyloid kinetics Assay. A ThT stock solution was made by
dissolving 2.5 mM Thioflavin-T (Merck-Schuchardt) in phosphate
buffer (10 mM phosphate, 150 mM NaCl, pH 7.4) and filtered
before use. This stock solution was diluted 50-fold in the
phosphate buffer to generate the working solution. Protein
samples of 10 mL of protein sample was taken added to 300 mL
of the working solution, and was allowed to bind the ThT for 1
min. ThT Fluorescence was measured using a FluoroMax-2
spectrofluorometer (Jobin Yvon/Psex Instruments) with excitation
and emission wavelengths of 440 and 48 5nm, respectively, and a
slit width of 5 nm. The ThT fluorescence intensities were
normalized to the fluorescence of the free dye in solution.
CD spectroscopy. CD spectra were recorded with a JASCO
J-720 spectropolarimeter equipped with a PTC-343 temperature
controller. For each sample, 3 spectra were acquired and averaged
in the range of 190 nm to 250 nm, using a 5 nm/min scan speed,
and 1 nm resolution. The quartz cells had a 1 mm optical path.
The contribution from the buffer was subtracted, and the results
are presented in relative ellipticity. The difference ellipticity in
Fig. 3 was obtained by subtracting the ellipticity of Ab1-40 peptide
(0.002 to 0.1 mM) and S100A9 (0.2 mM) complex with the ones
from 0.2 mM S100A9.
Electrophoresis. SDS and native polyacrylamide gel
electrophoresis (PAGE) was carried out on 15% Tris gels. 5
volume of protein sample was mixed with 1 volume of loading
buffer (1.6 ml Tris-HCl (1 M), 4 ml SDS (10%), 2 ml glycerol
(100%), 1 ml b-mercaptoethanol, 1.4 ml water and 4 mg
Bromophenol blue; SDS and b-mercaptoethanol are excluded
for native-PAGE). The electrophoretic separation was conducted
in a Mini Protean II Electrophoresis system (Biorad, USA) with a
running buffer (25 mM Tris and 192 mM glycine at pH 8.3; 0.3%
SDS was added for SDS PAGE). The standard protein ladder was
purchased from BioRad. Coomassie brilliant blue B7920 (Biorad,
USA) (0.125 g Coomassie Brilliant Blue R-250 in 200 ml
methanol, 35 ml acetic acid and 265 ml water, filtered before
use) was used for staining, and the following destaining step was
performed by using destaining agent (50% methanol, 10% acitic
acid and 40% water) for around 2 hours with gentle agitation.
Gas-phase electrophoretic mobility molecular analysis
(GEMMA). The operation procedure of GEMMA instrument
was as published previously [25]. S100A9 samples at pH 7.4 and
3.0 were exchanged against 20 mM ammonium acetate buffer (pH
7.4) by centrifugal ultrafiltration in Spin-X Centrifuge Tubes
(Sigma-Aldrich, USA) before loading into the capillary tube. The
operation current and voltage were approximately 300 nA and
2 kV respectively.
Atomic Force Microscopy (AFM). AFM measurements
were obtained with a PicoPlus AFM (Agilent) in tapping mode
using a 100 nm scanner in ambient conditions. Acoustically driven
cantilevers with etched silicon probes of the TESP model
(diameters of 10nm and less) (Digital Instruments) were used.
We applied a resonance frequency in the 170 kHz to 190 kHz
range, a scan rate of 1 Hz or less, and a resolution of 512
pixels6512 pixels. Height, amplitude and phase data were
collected simultaneously in trace and retrace modes to avoid
scan artifacts. Amyloid samples were deposited on the surface of
freshly cleaved mica (GoodFellow) for 5 min, washed 3 times with
200 ml of DI water and dried in air at room temperature.
Cell culture. SH-SY5Y (ATCC CRL-2266) were cultured in
Dulbecco’s modified Eagle medium supplemented with 10%(v/v)
FBS. Mixed cortical neuron cultures were prepared from
embryonic day 16.5 rat embryos. Animals used in this study
were maintained in strict accordance with the approval granted by
Umea Ethical Committee for Animal Experimentation (Permit
Number: A107–08). The cortical hemi-spheres were quickly
dissected in ice-cold phosphate saline buffers (PBS, pH 7.2) with
10 mM D-glucose. Cortices from 6–8 embryos were pooled and
neurons were isolated using the Papain Dissociation System
(Worthington Biochemical Corp). Viable cells were counted
following staining with 0.2% (w/v) trypan blue (Gibco/
Invitrogen) and plated at a density of 10,000 cells per well
(100,000 cells/ml) in a 96-well black-walled imaging plate (BD
Falcon). Neurons were cultured for 72 h in Neurobasal medium
(Invitrogen) containing 2% (v/v) NS21 supplement (Chen et al.
2008), 0.5 mM L-glutamine, 100 units/ml penicillin and 100 mg/
ml streptomycin in a humidified incubator (370C/5% (v/v) CO2).
WST1 cell viability assay. To evaluate cell viability, 10 mlo f
WST-1 reagent was added per 100 ml of cell culture and samples
were incubated at 370C for 4 h. The absorbance was measured
with an ELISA plate reader (Labsystem Multiscan RC) at 450 nm.
Cell viability was expressed as a percentage of the absorbance in
wells containing cells treated with amyloid compared to the
control cells.
Supporting Information
Figure S1 Ab1–40 peptide (0.2 mM) incubated at pH 7.4
and 370C for (a) 1 d; (b) 3 d. The scale bars denote 600 nm and
2000 nm, respectively. The insertions show the cross-section
profile of the fibrils corresponding to the marked positions. After
1 d incubation, proto-fibrils with a height of 0.5 nm were
observed. After 3 d, the surface was dominated by fibrils with a
height of 2 nm, which is typical for amyloid mature fibrils. As the
fibrils observed upon the addition of S100A9 (Fig. 1) carried a
height of 2 nm and the protofibrils are not necessarily related with
amyloid formation, it is reasonable to conclude that the presence
of S100A9 promotes the rate of formation and the quantity of
Ab1–40 amyloid species produced.
(TIF)
Figure S2 CD septra (a) The transition in the secondary
structures of (a) S100A9 (0.2 mM); (b) Ab1–40 peptide (0.2 mM).
Ellipticity of S100A9 (0.2 mM) with the addition of various
concentrations of Ab1–40 peptide (0.002 mM to 0.1 mM),
incubated at pH 7.4 and 370C for (c) 3 d; (d) 7 d. The insertions
denote the curves of 0.1 mM Ab1–40 in panel (c) and (d).
(TIF)
Figure S3 AFM height images of S100A9 (0.2 mM) (a)
incubated at pH 3.0 and 570C with continuous shaking at 800 rpm
for 3 d; (b) incubated at pH 3.0 and 370C for 3 d; (c) incubated at pH
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e329537.4and 370Cfor3d.Thescale barsrepresent 500nm,1000 nm and
500 nm, respectively. (d) CD spectra of the corresponding samples
shown in AFM: black squares correspond to Fig. (a); blue triangles
correspond to Fig. (b); red circles correspond to Fig. (c).
(TIF)
Figure S4 MeasurementsofNHSY5Ycell lineviabilityby
WST1 assay in the presence of (a): freshly dissolved Ab1–40 at
pH 7.4. Different colors denote different concentrations of Ab1–40.
(b): 0.2 mM Ab12–24 fibrils, 0.2 mM Ab1–40 fibrils and 0.2 mM
Ab1–40 plaque. Ab1–40 plaques were formed by incubation at pH
3.0 and 370C for 3 d. To avoid pH effect, pre-formed Ab plaques
werecarefullydialyzedtopH7.4.Ab12–24andAb1–40fibrilswere
formed by incubation at pH 7.4 and 370C for over 10 d. (c) The
relationship between the kinetics of S100A9 amyloid formation
(Relative ThT: left Y axis) at pH 3.0 and the effects of S100A9
(0.02 mM) on NHSY5Y cell viability (WST1 assay: right Y axis).
Before mixing with cells, S100A9 was incubated at pH 3.0 and 40C
for up to 70 d. Aliquots were taken for measurements of ThT and
cytotoxicity at different time during incubation. The columns in
each group correspond to 1 to 3 d of incubation with cells (In day 6
aliquots, S100A9 samples were incubated with cell for up to 2 d). (d)
Measurements of NHSY5Y cell line viability by WST1 assay in the
presence of S100A9 (0.02 mM) at pH 7.4 and 3.0. Different colors
denote 1 d to 3 d of incubation with cells.
(TIF)
Figure S5 (a) Luminescent cytotoxicity assay of neuron cells in
presence of 0.02 mM S100A9 and S100A9/Ab1–40 mixture.
S100A9 and the mixture were incubated at 370C for 3, 6, 12 and
24 h before mixing with cells. Ab1–40 plaques were formed by
incubation at pH 3.0 and 370C for 3 d. To avoid pH effect, pre-
formed Ab plaques were carefully dialyzed to pH 7.4 before
mixing with S100A9. Utilizing cortical neuron cells, the CytoTox-
Glo Cytotoxicity assay uses a luminogenic peptide substrate, the
AAF-Glo, to measure the activity of dead-cell protease, which is
released from cells that have lost membrane integrity. The AAF-
Glo substrate cannot cross intact cell membranes and does not
generate any appreciable signal from the live-cell population. (b)
Measurements of NHSY5Y cell line viability by WST1 assay in
the presence of freshly dissolved (1) 0.2 mM Ab12–24; (2) 0.2 mM
Ab12–24 and 0.02 mM S100A9 mixture; (3) 0.2 mM Ab1–16; (4)
0.2 mM Ab1–16 and 0.02 mM S100A9 mixture; (5) 0.2 mM
Ab1–42; (6) 0.2 mM Ab1–42 and 0.02 mM S100A9 mixture.
(TIF)
Figure S6 AFM images of (a) Ab12–24 peptide (0.2 mM)
incubated at pH 7.4 and 370C for 3 d; (b) the mixture of freshly
dissolved Ab12–24 peptide (0.2 mM) and S100A9 protein
(0.02 mM) incubated at pH 7.4 and 370C for 3 d; (c) Ab1–42
peptide (0.2 mM) incubated at pH 7.4 and 370C for 3 d; (d) the
mixture of freshly dissolved Ab1–42 peptide (0.2 mM) and S100A9
protein (0.02 mM) incubated at pH 7.4 and 370C for 3 d. In fig. a
and b, the scale bars denote 100 nm in the figure, and 1000 nm in
the insertion, respectively. The scale bars denote 200 nm in fig. c
and 500 nm in fig. d. With the addition of S100A9, large quantities
of Ab12–24 amyloid fibrils (2 nm in height) were formed, which is
similar in size with the mature Ab fibrils. In contrast, only
protofibrils (0.5 nm in height) were observed with Ab12–24 control
samples under the same conditions (panel a). Similarly, Ab fibrils
were only formed in the presence of S100A9 after 3 d incubation at
pH 7.4 and 370C. The average height of the fibrils in fig. d is 2 nm,
which is close to the reported value for Ab amyloid fibrils.
(TIF)
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